In vitro and in vivo activities of the novel azole antifungal agent r126638

Frank Christopher Odds, J. Ausma, F. Van Gerven, F. Woestenborghs, L. Meerpoel, J. Heeres, H. Vanden Bossche, M. Borgers

    Research output: Contribution to journalArticle

    42 Citations (Scopus)

    Abstract

    R126638 is a new triazole agent with potent antifungal activity in vitro against various dermatophytes, Candida spp., and Malassezia spp. Its activity against Malassezia spp. in vitro was superior to that of ketoconazole, the agent currently used for the treatment of Malassezia-related infections. R126638 showed activity comparable to or lower than that of itraconazole against dermatophytes in vitro; however, in guinea pig models of dermatophyte infections, R126638 given orally consistently showed antifungal activity superior to that of itraconazole, with 50% effective doses (ED(50)s) three- to more than eightfold lower than those of itraconazole, depending on the time of initiation and the duration of treatment. The ED50 of R126638 in a mouse dermatophytosis model was more than fivefold lower than that of itraconazole. These data indicate that if the effects of R126638 seen when it is used to treat animals can be extrapolated to humans, the novel compound would be expected to show effects at doses lower than those of existing drugs and, hence, present a lower risk for side effects.

    Original languageEnglish
    Pages (from-to)388-391
    Number of pages3
    JournalAntimicrobial Agents and Chemotherapy
    Volume48
    Issue number2
    DOIs
    Publication statusPublished - 2004

    Keywords

    • MALASSEZIA
    • DERMATITIS

    Cite this

    Odds, F. C., Ausma, J., Van Gerven, F., Woestenborghs, F., Meerpoel, L., Heeres, J., ... Borgers, M. (2004). In vitro and in vivo activities of the novel azole antifungal agent r126638. Antimicrobial Agents and Chemotherapy, 48(2), 388-391. https://doi.org/10.1128/AAC.48.2.388-391.2004

    In vitro and in vivo activities of the novel azole antifungal agent r126638. / Odds, Frank Christopher; Ausma, J.; Van Gerven, F.; Woestenborghs, F.; Meerpoel, L.; Heeres, J.; Vanden Bossche, H.; Borgers, M.

    In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 2, 2004, p. 388-391.

    Research output: Contribution to journalArticle

    Odds, FC, Ausma, J, Van Gerven, F, Woestenborghs, F, Meerpoel, L, Heeres, J, Vanden Bossche, H & Borgers, M 2004, 'In vitro and in vivo activities of the novel azole antifungal agent r126638', Antimicrobial Agents and Chemotherapy, vol. 48, no. 2, pp. 388-391. https://doi.org/10.1128/AAC.48.2.388-391.2004
    Odds, Frank Christopher ; Ausma, J. ; Van Gerven, F. ; Woestenborghs, F. ; Meerpoel, L. ; Heeres, J. ; Vanden Bossche, H. ; Borgers, M. / In vitro and in vivo activities of the novel azole antifungal agent r126638. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 2. pp. 388-391.
    @article{73bab9aabc414125ad534ba7aeee8155,
    title = "In vitro and in vivo activities of the novel azole antifungal agent r126638",
    abstract = "R126638 is a new triazole agent with potent antifungal activity in vitro against various dermatophytes, Candida spp., and Malassezia spp. Its activity against Malassezia spp. in vitro was superior to that of ketoconazole, the agent currently used for the treatment of Malassezia-related infections. R126638 showed activity comparable to or lower than that of itraconazole against dermatophytes in vitro; however, in guinea pig models of dermatophyte infections, R126638 given orally consistently showed antifungal activity superior to that of itraconazole, with 50{\%} effective doses (ED(50)s) three- to more than eightfold lower than those of itraconazole, depending on the time of initiation and the duration of treatment. The ED50 of R126638 in a mouse dermatophytosis model was more than fivefold lower than that of itraconazole. These data indicate that if the effects of R126638 seen when it is used to treat animals can be extrapolated to humans, the novel compound would be expected to show effects at doses lower than those of existing drugs and, hence, present a lower risk for side effects.",
    keywords = "MALASSEZIA, DERMATITIS",
    author = "Odds, {Frank Christopher} and J. Ausma and {Van Gerven}, F. and F. Woestenborghs and L. Meerpoel and J. Heeres and {Vanden Bossche}, H. and M. Borgers",
    year = "2004",
    doi = "10.1128/AAC.48.2.388-391.2004",
    language = "English",
    volume = "48",
    pages = "388--391",
    journal = "Antimicrobial Agents and Chemotherapy",
    issn = "0066-4804",
    publisher = "AMER SOC MICROBIOLOGY",
    number = "2",

    }

    TY - JOUR

    T1 - In vitro and in vivo activities of the novel azole antifungal agent r126638

    AU - Odds, Frank Christopher

    AU - Ausma, J.

    AU - Van Gerven, F.

    AU - Woestenborghs, F.

    AU - Meerpoel, L.

    AU - Heeres, J.

    AU - Vanden Bossche, H.

    AU - Borgers, M.

    PY - 2004

    Y1 - 2004

    N2 - R126638 is a new triazole agent with potent antifungal activity in vitro against various dermatophytes, Candida spp., and Malassezia spp. Its activity against Malassezia spp. in vitro was superior to that of ketoconazole, the agent currently used for the treatment of Malassezia-related infections. R126638 showed activity comparable to or lower than that of itraconazole against dermatophytes in vitro; however, in guinea pig models of dermatophyte infections, R126638 given orally consistently showed antifungal activity superior to that of itraconazole, with 50% effective doses (ED(50)s) three- to more than eightfold lower than those of itraconazole, depending on the time of initiation and the duration of treatment. The ED50 of R126638 in a mouse dermatophytosis model was more than fivefold lower than that of itraconazole. These data indicate that if the effects of R126638 seen when it is used to treat animals can be extrapolated to humans, the novel compound would be expected to show effects at doses lower than those of existing drugs and, hence, present a lower risk for side effects.

    AB - R126638 is a new triazole agent with potent antifungal activity in vitro against various dermatophytes, Candida spp., and Malassezia spp. Its activity against Malassezia spp. in vitro was superior to that of ketoconazole, the agent currently used for the treatment of Malassezia-related infections. R126638 showed activity comparable to or lower than that of itraconazole against dermatophytes in vitro; however, in guinea pig models of dermatophyte infections, R126638 given orally consistently showed antifungal activity superior to that of itraconazole, with 50% effective doses (ED(50)s) three- to more than eightfold lower than those of itraconazole, depending on the time of initiation and the duration of treatment. The ED50 of R126638 in a mouse dermatophytosis model was more than fivefold lower than that of itraconazole. These data indicate that if the effects of R126638 seen when it is used to treat animals can be extrapolated to humans, the novel compound would be expected to show effects at doses lower than those of existing drugs and, hence, present a lower risk for side effects.

    KW - MALASSEZIA

    KW - DERMATITIS

    U2 - 10.1128/AAC.48.2.388-391.2004

    DO - 10.1128/AAC.48.2.388-391.2004

    M3 - Article

    VL - 48

    SP - 388

    EP - 391

    JO - Antimicrobial Agents and Chemotherapy

    JF - Antimicrobial Agents and Chemotherapy

    SN - 0066-4804

    IS - 2

    ER -